Emvision Medical Devices Ltd. · ASX:EMV
Emvision Medical Devices — Shareholder Meeting (November 2021)
9 slides from Emvision Medical Devices's shareholder meeting presentation, Nov 25, 2021
Slide 1: AGM Chairman's Address & Presentation
25/11/21 EMvision Medical Devices Ltd ACN 620 388 230 Level 10, 12 Creek Street, Brisbane Qld 4000 02 8667 5337 contact@emvision.com.au AGM CHAIRMAN’S ADDRESS & PRESENTATION EMVision Medical Devices Limited (ASX: EMV) (“EMVision” or the “Company”), is pleased to provide the following Chairman’s addr
Slide 2: Contact details, About EMVision and Forward-looking Statements
For further information, media or investor enquiries, please contact: Andrew Keys Sling & Stone Scott Kirkland Investor Relations Media and Communications Executive Director +61 400 400 800 emvision@slingstone.com +61 2 8667 5337 andrew.keys@keysthomas.com 02 8073 5390 skirkland@emvision.com.au Abou
Slide 3: AGM 2021 CEO & Executive Team Presentation
www.emvision.com.au AGM - 2021 CEO & EXECUTIVE TEAM PRESENTATION
Slide 4: Team
TEAM Significant experience developing and commercialising medical devices Dr Ron Weinberger John Keep Scott Kirkland Prof Stuart Crozier Robert Tiller Forough Khandan CEO & MD Non-Executive Chairman Executive Director Chief Scientific Officer Head of Design Head of Product Development Former Nanoso
Slide 5: 2021 Highlights
2021 HIGHLIGHTS 1ST GEN SUCCESSFULLY MANUFACTURED First units built and undergoing verification and validation. Designed for portability, accessibility, speed, safety and to be as cost effective as possible. CLINICAL DATA & TECHNOLOGY ADVANCEMENTS DRIVES FURTHER CONFIDENCE New techniques, such as di
Slide 6: Depth and Talent
DEPTH AND TALENT W E H A V E B U I LT A T E A M W I T H A S U C C E S S F U L T R A C K R E C O R D I N D E L I V E R I N G I N N O V AT I V E M E D I C A L D E V I C E S F O R G L O B A L M A R K E T S Multi-disciplinary diverse team with a focus on specialist expertise: Radiofrequency Engineerin
Slide 7: 1st Gen: User Centered, Compliant and Reliable
1 ST GEN USER CENTERED, COMPLIANT AND RELIABLE o 1st generation pursuing FDA De Novo pathway – expected to become 510k predicate for future models o Distributed electrical and software architecture to provide agility, modular design, rapid verification and easy change management o Designed with manu
Slide 8: 2nd Gen: Setting Out to Transform Pre-Hospital Stroke Care
2 ND GEN S E T T I N G O U T T O T R A N S F O R M P R E - H O S P I TA L S T R O K E C A R E Bringing urgent neuro imaging to the patient, wherever they are. Reduce time to diagnosis, and open the door to earlier treatment Outputs link to telehealth, delivering images for fast review and clinical d
Slide 9: Clinical Investigations Roadmap & Milestones
CLINICAL INVESTIGATIONS ROADMAP & MILESTONES CY 22 H1 H2 CLINICAL INVESTIGATIONS ROADMAP 1ST GEN DEVICES PRE-VALIDATION – SITE 1-2 CENTRES: MULTI CENTRE LOCATION: EMERGENCY DEPARTMENT (ED) & WARDS UNDERGOING Patient total # to be enrolled TBC: Anticipated ~ 100-300 VERIFICATION AND 1. Preliminary us
Emvision Medical Devices — Shareholder Meeting (November 2021) on 6ix